343 related articles for article (PubMed ID: 22738661)
21. Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain Fusions.
Mittal N; Sengupta N; Malladi SK; Reddy P; Bhat M; Rajmani RS; Sedeyn K; Saelens X; Dutta S; Varadarajan R
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578291
[TBL] [Abstract][Full Text] [Related]
22. Protection against H1N1 influenza challenge by a DNA vaccine expressing H3/H1 subtype hemagglutinin combined with MHC class II-restricted epitopes.
Tan L; Lu H; Zhang D; Tian M; Hu B; Wang Z; Jin N
Virol J; 2010 Dec; 7():363. PubMed ID: 21134292
[TBL] [Abstract][Full Text] [Related]
23. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
[TBL] [Abstract][Full Text] [Related]
24. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.
Chen Z; Matsuo K; Asanuma H; Takahashi H; Iwasaki T; Suzuki Y; Aizawa C; Kurata T; Tamura S
Vaccine; 1999 Feb; 17(7-8):653-9. PubMed ID: 10067670
[TBL] [Abstract][Full Text] [Related]
25. Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.
Allen JD; Ross TM
J Virol; 2022 Apr; 96(7):e0165221. PubMed ID: 35289635
[TBL] [Abstract][Full Text] [Related]
26. Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.
Wang BZ; Gill HS; Kang SM; Wang L; Wang YC; Vassilieva EV; Compans RW
Clin Vaccine Immunol; 2012 Aug; 19(8):1119-25. PubMed ID: 22647270
[TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of antibody induction and protection against influenza virus infection by DNA immunization with HA, HAe, and HA1 in mice.
Chen J; Liu Q; Chen Q; Xiong C; Yao Y; Wang H; Wang H; Chen Z
Arch Virol; 2014 Apr; 159(4):689-700. PubMed ID: 24132721
[TBL] [Abstract][Full Text] [Related]
28. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
29. A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection.
Bragstad K; Vinner L; Hansen MS; Nielsen J; Fomsgaard A
Vaccine; 2013 Apr; 31(18):2281-8. PubMed ID: 23499598
[TBL] [Abstract][Full Text] [Related]
30. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
Wang W; Huang B; Wang X; Tan W; Ruan L
Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
[TBL] [Abstract][Full Text] [Related]
31. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.
Kim MC; Lee YN; Kim YJ; Choi HJ; Kim KH; Lee YJ; Kang SM
Antiviral Res; 2017 Dec; 148():43-52. PubMed ID: 29107058
[TBL] [Abstract][Full Text] [Related]
33. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice.
Zhou C; Zhou L; Chen YH
Vaccine; 2012 May; 30(23):3463-9. PubMed ID: 22446634
[TBL] [Abstract][Full Text] [Related]
34. Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice.
Wu Y; Yang D; Xu B; Liang W; Sui J; Chen Y; Yang H; Chen H; Wei P; Qiao C
Antiviral Res; 2017 Nov; 147():29-36. PubMed ID: 28941982
[TBL] [Abstract][Full Text] [Related]
35. Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs.
Braucher DR; Henningson JN; Loving CL; Vincent AL; Kim E; Steitz J; Gambotto AA; Kehrli ME
Clin Vaccine Immunol; 2012 Nov; 19(11):1722-9. PubMed ID: 22933397
[TBL] [Abstract][Full Text] [Related]
36. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
38. A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus.
Chang H; Huang C; Wu J; Fang F; Zhang W; Wang F; Chen Z
Virol J; 2010 Aug; 7():197. PubMed ID: 20727202
[TBL] [Abstract][Full Text] [Related]
39. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
40. A prime-boost concept using a T-cell epitope-driven DNA vaccine followed by a whole virus vaccine effectively protected pigs in the pandemic H1N1 pig challenge model.
Hewitt JS; Karuppannan AK; Tan S; Gauger P; Halbur PG; Gerber PF; De Groot AS; Moise L; Opriessnig T
Vaccine; 2019 Jul; 37(31):4302-4309. PubMed ID: 31248687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
